Physician profile
John Swing
NPI 1366493686
$63,464.06
in general payments reported to CMS, 2019-2025
19 companies · $1,388 in 2025
The $1,388 reported for 2025 was more than what 85% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $7,902 · 2021: $8,070 · 2022: $7,867 · 2023: $16K · 2024: $5,429 · 2025: $1,388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Food and Beverage: $3,508 · Travel and Lodging: $1,997 · Education: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,000.00 |
| Food and Beverage | $3,508.04 |
| Travel and Lodging | $1,996.53 |
| Education | $118.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $31,598.73 | 2021-2025 | Vraylar |
| Allergan, INC. | $26,983.51 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $826.59 | 2020-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $720.51 | 2019-2025 | Uzedy, Austedo Xr |
| Neurocrine Biosciences, INC. | $644.94 | 2019-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $484.67 | 2019-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| E.R. Squibb & Sons, L.L.C. | $344.09 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $327.27 | 2019-2025 | Abilify Asimtufii, Rexulti |
| Janssen Pharmaceuticals, INC | $307.56 | 2019-2025 | Invega Sustenna |
| Alkermes, INC. | $303.05 | 2019-2025 | Aristada, Lybalvi |
| Sunovion Pharmaceuticals INC. | $268.11 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $198.27 | 2019-2025 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $140.61 | 2019-2021 | |
| Axsome Therapeutics, INC. | $140.06 | 2024-2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $51.17 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $38.91 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $35.24 | 2021 | |
| Ironshore Pharmaceuticals INC. | $27.78 | 2019-2020 | |
| Shire North American Group INC | $22.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Swing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.